TY  - JOUR
T1  - S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease
AU  - Leiter, Ulrike
AU  - Heppt, Markus V.
AU  - Amaral, Teresa
AU  - Bauer, Andrea
AU  - Becker, Jürgen C.
AU  - Breitbart, Eckhardt
AU  - Breuninger, Helmut
AU  - Diepgen, Thomas
AU  - Dirschka, Thomas
AU  - Faig, Michael
AU  - Follmann, Markus
AU  - Fritz, Klaus
AU  - Greinert, Rüdiger
AU  - Gutzmer, Ralf
AU  - Hillen, Uwe
AU  - Ihrler, Stephan
AU  - John, Swen Malte
AU  - Kölbl, Oliver
AU  - Kraywinkel, Klaus
AU  - Löser, Christoph
AU  - Nashan, Dorothee
AU  - Noor, Seema
AU  - Nothacker, Monika
AU  - Pfannenberg, Christina
AU  - Salavastru, Carmen
AU  - Schmitz, Lut
AU  - Stockfleth, Eggert
AU  - Szeimies, Rolf-Markus
AU  - Ulrich, Claas
AU  - Welzel, Julia
AU  - Wermker, Kai
AU  - Garbe, Claus
AU  - Berking, Carola
AB  - Actinic keratoses (AKs) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guidelines for actinic keratosis and cutaneous squamous cell carcinoma were developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guidelines are aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AKs and cSCC. The guidelines are also aimed at affected patients, their relatives, policy makers and insurance funds. In the second part, we will address aspects relating to epidemiology, etiology, surgical and systemic treatment of cSCC, follow-up and disease prevention, and discuss AKs and cSCC in the context of occupational disease regulations.
KW  - 610 Medizin und Gesundheit
PY  - 2020
LA  - eng
PB  - Robert Koch-Institut
JO  - Journal der deutschen Dermatologischen Gesellschaft
VL  - 18
IS  - 4
SP  - 400
EP  - 413
DO  - 10.1111/ddg.14072
ER  -